Session » Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)
-
Abstract Number: 0908
Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Multicenter, Randomised, Double-blind, Phase IV Study
-
Abstract Number: 0909
How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
-
Abstract Number: 0910
The Association of TNF Inhibitor Use with Incident Hypertension in Ankylosing Spondylitis: Data from the PSOAS Cohort
-
Abstract Number: 0911
Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis
-
Abstract Number: 0912
Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients with Early versus Late Disease Through Week 52 of GO-ALIVE Study
-
Abstract Number: 0913
Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Active Non‑Radiographic Axial Spondyloarthritis: 3-Year Results from a Phase 3 Multicenter Study
-
Abstract Number: 0914
Response to Certolizumab Pegol in Patients with Non-Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Cut-Offs: Post-Hoc Analysis from a Phase 3 Multicenter Study
-
Abstract Number: 0915
Biomarkers of Extracellular Matrix Turnover Reflect Treatment Response and Pharmacodynamic Effects of TNF-α Inhibitory Therapy in Patients with Axial Spondyloarthritis
-
Abstract Number: 0916
Disease Activity and Inflammation in Axial Spondyloarthritis Patients Who Did Not Experience Flares Following Certolizumab Pegol Withdrawal, Dose Reduction or Dose Continuation
-
Abstract Number: 0917
Efficacy of Secukinumab and HLA-B27 Subtypes: Results from a Phase IIIb Randomised Controlled Trial in Axial SpA
-
Abstract Number: 0919
Ixekizumab Shows a Distinct Pattern of Pain Improvement Beyond Measurable Inflammation as Assessed by MRI or CRP or BASDAI Questions 5 & 6 in Patients with Ankylosing Spondylitis
-
Abstract Number: 0920
Influence of Baseline Demographics on Improvements in Disease Activity Measures in Patients with Ankylosing Spondylitis Receiving Upadacitinib: A Post Hoc Subgroup Analysis
-
Abstract Number: 0922
Bimekizumab Shows Sustained and Meaningful Long-Term Improvements in Health-Related Quality of Life in Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study
-
Abstract Number: 0924
Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
-
Abstract Number: 0925
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs
-
Abstract Number: 0926
Predictors of 1-Year Treatment Response Among Upadacitinib-Treated Patients with Ankylosing Spondylitis: A Post Hoc Analysis
-
Abstract Number: 0927
Whole Blood Transcriptional Changes Following Treatment with Filgotinib in Patients with Ankylosing Spondylitis
-
Abstract Number: 0928
Filgotinib Treatment Results in Reduction of Inflammatory and Matrix Remodeling Biomarkers Associated with Disease in Patients with Ankylosing Spondylitis
-
Abstract Number: 0929
Tapering of TNF Inhibitors in Patients with Axial Spondyloartritis – Can Flare Be Predicted?
-
Abstract Number: 0932
Sequential Treatment in Axial Spondyloarthritis – Real World Data from a Network of German Rheumatologists
-
Abstract Number: 0933
Sustained Functional Remission in Axial Spondyloarthritis (axSpA): Which Are the Primary Outcomes That Should Be Targeted to Achieve This?
-
Abstract Number: 0935
Effects of Ixekizumab Treatment on Structural Changes in the Sacroiliac Joints Based on MRI Assessments at 16 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis
-
Abstract Number: 0936
Factors Associated with the Development of Anti-drug Antibodies to Tumour Necrosis Factor Inhibitors in Patients with Axial Spondyloarthritis; A Two Year Follow-up Study
-
Abstract Number: 0937
Evaluation of the Safety of Vedolizumab in Combination with Other Immunosuppression Biological Therapy in Patients with Inflammatory Bowel Disease